EGFR and non-small cell lung carcinoma: These findings indicate that BIQO-19 re-sensitizes EGFR-TKI-resistant NSCLC cells to gefitinib; combined treatment with BIQO-19 and gefitinib synergistically inhibits cell proliferation and induces apoptosis in H1975 cells.